cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.31354273
title: Postoperative early mobilisation protocol for endometrial cancer patients: a retrospective study

description: Standardised early mobilisation within Enhanced Recovery After Surgery (ERAS) for endometrial cancer is lacking. This study developed and evaluated a protocol. This retrospective study analysed outcomes of a clinical quality improvement initiative conducted at a tertiary care centre (February 2021–May 2022). <i>Phase 1</i>: Protocol developed via evidence/expert consensus. <i>Phase 2</i>: Retrospective analysis of 90 patients who received care in two units during the study period. Patients admitted to unit A (<i>n</i> = 45) received a structured early mobilisation protocol implemented as part of routine clinical practice improvement, whilst patients admitted to unit B (<i>n</i> = 45) received standard care. Ward assignment was determined by bed availability at admission without researcher involvement in allocation. <i>Primary outcomes</i>: Pulmonary function, physical capacity (ambulation time/day 5 walking distance) and gastrointestinal recovery. <i>Secondary</i>: Complications, LOS, emotional status (Brief Profile of Mood States, BPOMS). Statistical analyses included effect sizes and 95% confidence intervals. The intervention group was associated with significantly better first ambulation (6.8 ± 2.1 h vs. 18.5 ± 4.3 h, mean difference: 11.7 h, 95% CI: 10.3–13.1, <i>p</i> &lt; 0.001), day 5 walking distance (385 ± 68 m vs. 142 ± 45 m, mean difference: 243 m, 95% CI: 220–266, <i>p</i> &lt; 0.001), time to first flatus (28.5 ± 6.2 h vs. 48.3 ± 8.5 h, mean difference: 19.8 h, 95% CI: 16.9–22.7, <i>p</i> &lt; 0.001), fewer pulmonary complications (8.9% vs. 24.4%, OR: 0.30, 95% CI: 0.09–0.96, <i>p</i> = 0.047), shorter LOS (4.2 ± 1.1 d vs. 6.8 ± 1.5 d, mean difference: 2.6 d, 95% CI: 2.0–3.2, <i>p</i> &lt; 0.001) and improved BPOMS anxiety/depression scores. This retrospective analysis suggests that the structured early mobilisation protocol, implemented as a clinical quality improvement initiative, was associated with improved recovery, reduced complications/LOS and better emotional wellbeing in endometrial cancer patients within ERAS. Early movement after cancer surgery helps patients recover faster. This study developed and tested a structured plan to help women with endometrial cancer (cancer of the womb) move around soon after their operation. We compared 45 women who followed this new plan with 45 women who received usual care. Women following the new plan started walking much sooner after surgery (about seven hours vs. 19 hours), walked further distances, and had their bowel function return faster. They also had fewer lung problems, went home about three days earlier, and felt less anxious and sad. The study shows that having a clear, step-by-step plan for movement after surgery can help women recover better and faster. This is especially important because many patients and families in China traditionally believe that resting in bed after surgery is best. Our results show that gentle, guided movement is actually better for recovery.
DOI: 10.6084/m9.figshare.31354273.v1
title: Postoperative early mobilisation protocol for endometrial cancer patients: a retrospective study

description: Standardised early mobilisation within Enhanced Recovery After Surgery (ERAS) for endometrial cancer is lacking. This study developed and evaluated a protocol. This retrospective study analysed outcomes of a clinical quality improvement initiative conducted at a tertiary care centre (February 2021–May 2022). <i>Phase 1</i>: Protocol developed via evidence/expert consensus. <i>Phase 2</i>: Retrospective analysis of 90 patients who received care in two units during the study period. Patients admitted to unit A (<i>n</i> = 45) received a structured early mobilisation protocol implemented as part of routine clinical practice improvement, whilst patients admitted to unit B (<i>n</i> = 45) received standard care. Ward assignment was determined by bed availability at admission without researcher involvement in allocation. <i>Primary outcomes</i>: Pulmonary function, physical capacity (ambulation time/day 5 walking distance) and gastrointestinal recovery. <i>Secondary</i>: Complications, LOS, emotional status (Brief Profile of Mood States, BPOMS). Statistical analyses included effect sizes and 95% confidence intervals. The intervention group was associated with significantly better first ambulation (6.8 ± 2.1 h vs. 18.5 ± 4.3 h, mean difference: 11.7 h, 95% CI: 10.3–13.1, <i>p</i> &lt; 0.001), day 5 walking distance (385 ± 68 m vs. 142 ± 45 m, mean difference: 243 m, 95% CI: 220–266, <i>p</i> &lt; 0.001), time to first flatus (28.5 ± 6.2 h vs. 48.3 ± 8.5 h, mean difference: 19.8 h, 95% CI: 16.9–22.7, <i>p</i> &lt; 0.001), fewer pulmonary complications (8.9% vs. 24.4%, OR: 0.30, 95% CI: 0.09–0.96, <i>p</i> = 0.047), shorter LOS (4.2 ± 1.1 d vs. 6.8 ± 1.5 d, mean difference: 2.6 d, 95% CI: 2.0–3.2, <i>p</i> &lt; 0.001) and improved BPOMS anxiety/depression scores. This retrospective analysis suggests that the structured early mobilisation protocol, implemented as a clinical quality improvement initiative, was associated with improved recovery, reduced complications/LOS and better emotional wellbeing in endometrial cancer patients within ERAS. Early movement after cancer surgery helps patients recover faster. This study developed and tested a structured plan to help women with endometrial cancer (cancer of the womb) move around soon after their operation. We compared 45 women who followed this new plan with 45 women who received usual care. Women following the new plan started walking much sooner after surgery (about seven hours vs. 19 hours), walked further distances, and had their bowel function return faster. They also had fewer lung problems, went home about three days earlier, and felt less anxious and sad. The study shows that having a clear, step-by-step plan for movement after surgery can help women recover better and faster. This is especially important because many patients and families in China traditionally believe that resting in bed after surgery is best. Our results show that gentle, guided movement is actually better for recovery.
DOI: 10.6084/m9.figshare.31226376
title: Provider perceptions on the clinical utility of pharmacogenomics testing: views of psychiatry physicians from an academic center

description: Provider attitudes on the clinical applicability of pharmacogenomics (PGx) are variable. We investigated psychiatry provider perspectives on PGx testing to gauge familiarity, implementation barriers/facilitators, and educational gaps within the Johns Hopkins Health System (JHHS). A 63-question survey was disseminated to psychiatry attending physicians and trainees practicing at JHHS. The survey queried familiarity with PGx testing, its clinical utility, barriers, benefits, the future landscape of PGx, and improvements in PGx implementation. Responses were categorized using a Likert scale and analyzed with Mann–Whitney non-parametric statistical testing. Within our health system, a minority of respondents were aware of PGx resources and there was mixed comfortability in the utilization and interpretation of PGx results. There were mixed opinions regarding the current clinical benefits of PGx testing but there was a desire for further education/training and strong agreement regarding the increased role of PGx in the future of psychiatric practice. Areas where PGx could be improved for greater clinical integration were also identified. While current PGx perspectives are mixed, there is agreement that PGx will play a greater role in psychiatry, highlighting the importance of PGx education and testing integration within a framework which promotes multi-disciplinary consultation to overcome implementation and interpretation challenges.
DOI: 10.6084/m9.figshare.31226376.v1
title: Provider perceptions on the clinical utility of pharmacogenomics testing: views of psychiatry physicians from an academic center

description: Provider attitudes on the clinical applicability of pharmacogenomics (PGx) are variable. We investigated psychiatry provider perspectives on PGx testing to gauge familiarity, implementation barriers/facilitators, and educational gaps within the Johns Hopkins Health System (JHHS). A 63-question survey was disseminated to psychiatry attending physicians and trainees practicing at JHHS. The survey queried familiarity with PGx testing, its clinical utility, barriers, benefits, the future landscape of PGx, and improvements in PGx implementation. Responses were categorized using a Likert scale and analyzed with Mann–Whitney non-parametric statistical testing. Within our health system, a minority of respondents were aware of PGx resources and there was mixed comfortability in the utilization and interpretation of PGx results. There were mixed opinions regarding the current clinical benefits of PGx testing but there was a desire for further education/training and strong agreement regarding the increased role of PGx in the future of psychiatric practice. Areas where PGx could be improved for greater clinical integration were also identified. While current PGx perspectives are mixed, there is agreement that PGx will play a greater role in psychiatry, highlighting the importance of PGx education and testing integration within a framework which promotes multi-disciplinary consultation to overcome implementation and interpretation challenges.
DOI: 10.6084/m9.figshare.31227944
title: UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients

description: Deferiprone, an iron chelator, causes variable adverse drug reactions (ADRs) in β-thalassemia patients, suggesting a role for pharmacogenetic factors. To address the lack of comprehensive pharmacogenetic data, this study investigated the association between four common <i>UGT1A6</i> variants – the primary enzyme metabolizing deferiprone – and the occurrence of specific ADRs, considering relevant clinical and personal characteristics. A retrospective cohort of 178 Iranian β-thalassemia major patients on deferiprone was studied. ADRs – arthralgia, gastrointestinal (GI) complications, neutropenia, and liver enzyme elevations – were defined using clinical guidelines, confirmed by medical records, and supplemented by questionnaires. Four UGT1A6 polymorphisms were genotyped, and associations were evaluated using a complication-specific framework and diplotype – haplotype analyses, adjusting for ten demographic, clinical, and treatment variables. Overall ADR incidence was not significantly associated with individual SNPs. Stratified analysis revealed that the AA – GC diplotype (rs2070959–rs1105879) was associated with reduced arthralgia risk (OR = 0.28, <i>p</i> = 0.022), whereas the GC – AC diplotype was linked to increased GI complication risk (OR = 5.48, <i>p</i> = 0.007) and showed a near-significant association with neutropenia. Female sex was associated only with increased GI complications (<i>p</i> = 0.002). Specific UGT1A6 diplotypes and sex are differentially associated with distinct deferiprone-related ADRs. A complication-specific pharmacogenetic approach can improve understanding of deferiprone-related ADRs.
DOI: 10.6084/m9.figshare.31227944.v1
title: UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients

description: Deferiprone, an iron chelator, causes variable adverse drug reactions (ADRs) in β-thalassemia patients, suggesting a role for pharmacogenetic factors. To address the lack of comprehensive pharmacogenetic data, this study investigated the association between four common <i>UGT1A6</i> variants – the primary enzyme metabolizing deferiprone – and the occurrence of specific ADRs, considering relevant clinical and personal characteristics. A retrospective cohort of 178 Iranian β-thalassemia major patients on deferiprone was studied. ADRs – arthralgia, gastrointestinal (GI) complications, neutropenia, and liver enzyme elevations – were defined using clinical guidelines, confirmed by medical records, and supplemented by questionnaires. Four UGT1A6 polymorphisms were genotyped, and associations were evaluated using a complication-specific framework and diplotype – haplotype analyses, adjusting for ten demographic, clinical, and treatment variables. Overall ADR incidence was not significantly associated with individual SNPs. Stratified analysis revealed that the AA – GC diplotype (rs2070959–rs1105879) was associated with reduced arthralgia risk (OR = 0.28, <i>p</i> = 0.022), whereas the GC – AC diplotype was linked to increased GI complication risk (OR = 5.48, <i>p</i> = 0.007) and showed a near-significant association with neutropenia. Female sex was associated only with increased GI complications (<i>p</i> = 0.002). Specific UGT1A6 diplotypes and sex are differentially associated with distinct deferiprone-related ADRs. A complication-specific pharmacogenetic approach can improve understanding of deferiprone-related ADRs.
DOI: 10.6084/m9.figshare.31113129
title: Pharmacogenomic testing for Prader-Willi syndrome: a mixed methods analysis of caregiver experiences and utilization

description: This study aims to better understand the utility of pharmacogenomic (PGx) testing for the rare disease, Prader-Willi syndrome (PWS). Individuals with PWS received PGx testing, and their caregivers were surveyed 1 month after receiving results (<i>n</i> = 42) and 6-months after receiving results (<i>n</i> = 38). A subset of respondents (<i>n</i> = 9) also participated in qualitative interviews. After receiving the PGx results, only one caregiver participant (2.27%) reported making medication changes. Eighty percent of caregiver participants stated the most valuable aspect of the PGx results was the information it provided about future medications their child may need. Interview participants discussed how the report gave them reassurance or verification of their current medication regimen. Only 36.59% of caregiver participants shared PGx results with their child’s healthcare providers during the six-month follow-up period. Interview participants described reasons for not sharing the PGx report, including that nothing in the report prompted them to do so, or that they believed providers would not use it. PGx results are perceived as valuable to the PWS population, but sharing PGx results with healthcare providers was limited at the six-month time point. This study explored whether a type of genetic testing, pharmacogenomic (PGx) testing, was useful for those with a rare condition called Prader-Willi syndrome (PWS). Those with PWS underwent this testing to see if this could help with choosing medicines. Their caregivers completed a survey 1 month and 6 months after getting their results and some took part in interviews. Most caregivers found this testing helpful to learn what medicines their child might need in the future. Some caregivers said the testing gave them confidence about their child’s current medicines. Not many caregivers shared the results with their child’s doctors because nothing had happened to make them share the results or they thought the doctors might not use this information now. Overall, caregivers found this testing helpful, but many did not share this with their doctors.
DOI: 10.6084/m9.figshare.31113129.v1
title: Pharmacogenomic testing for Prader-Willi syndrome: a mixed methods analysis of caregiver experiences and utilization

description: This study aims to better understand the utility of pharmacogenomic (PGx) testing for the rare disease, Prader-Willi syndrome (PWS). Individuals with PWS received PGx testing, and their caregivers were surveyed 1 month after receiving results (<i>n</i> = 42) and 6-months after receiving results (<i>n</i> = 38). A subset of respondents (<i>n</i> = 9) also participated in qualitative interviews. After receiving the PGx results, only one caregiver participant (2.27%) reported making medication changes. Eighty percent of caregiver participants stated the most valuable aspect of the PGx results was the information it provided about future medications their child may need. Interview participants discussed how the report gave them reassurance or verification of their current medication regimen. Only 36.59% of caregiver participants shared PGx results with their child’s healthcare providers during the six-month follow-up period. Interview participants described reasons for not sharing the PGx report, including that nothing in the report prompted them to do so, or that they believed providers would not use it. PGx results are perceived as valuable to the PWS population, but sharing PGx results with healthcare providers was limited at the six-month time point. This study explored whether a type of genetic testing, pharmacogenomic (PGx) testing, was useful for those with a rare condition called Prader-Willi syndrome (PWS). Those with PWS underwent this testing to see if this could help with choosing medicines. Their caregivers completed a survey 1 month and 6 months after getting their results and some took part in interviews. Most caregivers found this testing helpful to learn what medicines their child might need in the future. Some caregivers said the testing gave them confidence about their child’s current medicines. Not many caregivers shared the results with their child’s doctors because nothing had happened to make them share the results or they thought the doctors might not use this information now. Overall, caregivers found this testing helpful, but many did not share this with their doctors.
DOI: 10.15468/dl.7twue9
title: Occurrence Download

description: A dataset containing 402 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Human Observation",
 "Country is Ecuador",
 "OccurrenceStatus is Present",
 "TaxonKey is Lonchura malacca (Linnaeus, 1766)"
 ]
}

 The dataset includes 402 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0007462-250415084134356/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.3535/lyf-242-tre
title: Carex pilulifera L.

description: Digital Specimen for the physical specimen hosted at Natural History Museum Vienna.
DOI: 10.5281/zenodo.16094742
title: Modeling Stock Yield Reaction to Environmental Changes: Does Geopolitical Risk Matter? A VECM Framework in China
DOI: 10.5281/zenodo.16094743
title: Modeling Stock Yield Reaction to Environmental Changes: Does Geopolitical Risk Matter? A VECM Framework in China
DOI: 10.15468/dl.tf2hcp
title: Occurrence Download

description: A dataset containing 375 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Parectopa robiniella",
 "Country is Slovenia",
 "HasCoordinate is true"
 ]
}

 The dataset includes 375 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006783-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.mj4gvs
title: Occurrence Download

description: A dataset containing 54 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Lepidium afghanicum"
 ]
}

 The dataset includes 54 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006784-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.v493y2
title: Occurrence Download

description: A dataset containing 918 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Euphorbia platyphyllos stricta, Euphorbia platyphyllos stricta, Euphorbia serrulata, Euphorbia sticta, Euphorbia stricta pubescens, Euphorbia stricta micrantha, Euphorbia stricta pubescens, Galarhoeus micranthus, Galarhoeus platyphyllus strictus, Galarhoeus strictus)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen, Machine Observation)"
 ]
 }
 },
 "Continent is Europe",
 "Year is greater than or equal to 1980",
 "Year is less than or equal to 2024"
 ]
}

 The dataset includes 918 records from 48 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006785-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.662re5
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Balanus improvisus",
 "Country is Australia",
 "HasCoordinate is true"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006787-250717081556266/datasets/export for details.
DOI: 10.3535/jqz-za3-zea
title: Pallenis spinosa (L.) Cass.

description: Digital Specimen for the physical specimen hosted at Natural History Museum Vienna.
DOI: 10.15468/dl.qk8tv9
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Salvinia molesta",
 "Country is Mauritius",
 "HasCoordinate is true"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006788-250717081556266/datasets/export for details.
DOI: 10.5281/zenodo.16093780
title: Labeled Human Facial Pain Expressions Dataset with Intensity Annotations
DOI: 10.5281/zenodo.16093781
title: Labeled Human Facial Pain Expressions Dataset with Intensity Annotations
DOI: 10.15468/dl.4zwpna
title: Occurrence Download

description: A dataset containing 4664 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "TaxonKey is one of (Desmognathus quadramaculatus)"
 ]
}

 The dataset includes 4664 records from 39 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006789-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.49awc9
title: Occurrence Download

description: A dataset containing 1054 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Senecio lautus"
 ]
}

 The dataset includes 1054 records from 43 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006791-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.15742626
title: Raman Databases for RamanLab software

description: V2: Precompiled and ready to go databases from the RRUFF, SLOPP/E, and WURM public databases fro Raman spectra.  These datasets are already formatted for the RamanLab software. Download them, and put them in the top level of the RamanLab directory.
DOI: 10.15468/dl.2zsayf
title: Occurrence Download

description: A dataset containing 2 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Balanus improvisus",
 "Country is Denmark",
 "HasCoordinate is true"
 ]
}

 The dataset includes 2 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006794-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.kvdv87
title: Occurrence Download

description: A dataset containing 162 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Capparis ferruginea"
 ]
}

 The dataset includes 162 records from 27 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006790-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.